Larry Tiffany | CEO, GenrAb – Developing Fully Human Neuroprotective Antibodies for Neurodegenerative Diseases
Update: 2025-09-08
Description
In this episode of Executive Insights for Life Sciences Innovators, we sit down with Larry Tiffany, CEO of GenrAb, to explore how the company is developing fully human neuroprotective antibodies to address neurodegenerative diseases such as ALS, Parkinson’s, and Alzheimer’s. Larry discusses GenrAb’s scientific approach, the promise of neuroprotection in slowing disease progression, and the challenges of advancing novel biologics in today’s biotech landscape.
Learn more at genecoda.com.
Originally recorded and streamed on YouTube Live on June 20, 2025.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
